Intelligent Monitoring Group Limited (IMB) Earnings Call Transcript & Summary

July 25, 2025

Australian Securities Exchange AU Industrials Commercial Services and Supplies earnings 33 min

Earnings Call Speaker Segments

Mark Tobin

executive
#1

June 4 is arriving from every direction, it seems. I’ll briefly go through these opening slides, and then we’ll move right into it with our first presenter. If anyone is with us for the first time, I’m Mark Tobin. I’m the founder of Coffee Microcaps. You’re very welcome. To all our regular attendees, welcome back to this morning’s webinar. I want to give a special mention to RaaS Research Service, our virtual event sponsor here. If you’re looking for some coverage of stocks in the smaller micro cap space, please do check out their website. They’ve got a free version, and they’ve also launched a subscription version now that you can join up to for some broader coverage and insights. A quick compliance and disclaimer side, and as always, a very warm welcome to our friends from ASIC if they’re joining us this morning. For anybody who is joining us for the first time, stocks we tend to have on here are capped under $300 million. That’s our definition of a micro cap. Tend to be in revenue, approaching cash flow breakeven, or indeed already profitable. We tend not to have resources and biotechs on here.

Mark Tobin

executive
#2

They don't really fit into that second category, if you will. What I tend to refer to as industry micro caps, and that sort of encompasses everything else across financial services, healthcare, technology, and industrial companies. This morning, we have two companies presenting over the next hour, 30 minutes each. We'll aim to split that into roughly a 20-minute presentation and 10 minutes of Q&A. Should you have any questions for our presenters, please type them into the Q&A box. It may be located under the more drop-down menu on your screen. Please be aware the webinar is being recorded, and it will be posted on the Coffee Microcaps YouTube channel on Monday morning. You can follow us on Twitter. That's still what I call it. I'm too old school to call it X. YouTube for this recording and all our previous ones. We've had a couple of interviews with fund managers of late leading into reporting season. If you're looking for some stocks to keep an eye on as we move through the back end of July and into August, please check those out. We'll have a few more companies presenting next week. LinkedIn, you can guess, and there's also a monthly newsletter that generally goes out the first week of the month.

Mark Tobin

executive
#3

This morning's first presenter is someone I'm very happy to welcome back — Dennison Hambling from Intelligent Monitoring Group. We'll also have another familiar face returning, Steven Lynam, who joins us from Melbourne from Immuron. If anyone happened to spot it, we somehow ended up with two tickers sitting side by side on the ASX, IMB and IMC. Out of 2,000, we managed to line that up, which is funny. Let me bring up our first presenter now, Dennison Hambling from Intelligent Monitoring Group. Dennison, good morning.

Dennison Hambling

executive
#4

Morning, Mark. Thanks to all of you.

Mark Tobin

executive
#5

I'll stop sharing my screen now, Dennison. If you'd like to bring up your presentation deck, just let me know when it's visible to me. Yeah, it's loading at the moment, Dennison. Yeah, the cover slide is showing for me now, mate.

Dennison Hambling

executive
#6

Okay, thanks, Mark. I'll get things started. Appreciate everyone taking the time today. What we want to do is move fairly briskly through a pre-zone, then get to the cash flows, give a brief business update, and after that head straight to questions. As you know, our results came out this morning. Before we begin, a quick reminder of what Intelligent Monitoring Group is — IMB is the ticker. We're now the top security monitoring and services business across Australasia. Our footprint has been expanding fast, mainly under the ADT brand throughout Australasia, stretching from the top of Cape York down to the bottom of Stewart Island. That provides tremendous strategic reach and advantage as we pursue commercial enterprise security customers and also collaborate independently with our security partners across the industry. Plenty of businesses nationwide want to take advantage of our now-leading technology. More than 200,000 customers, and a strongly recurring revenue model. I believe during this coming season — the full year results season and so on — we'll begin really emphasizing that and bringing out the full extent of the recurring characteristics of our business. Roughly 599 employees, plus a nicely balanced and highly supportive register, which I'm very grateful for.

Dennison Hambling

executive
#7

Thanks again to everyone for making time today. On how we present ourselves, we're quite clear about it. We've put a lot of work and thought into understanding how our business operates. The ADT brand is one you'll be familiar with. ADT is our direct-to-customer operation. Should you call me or a member of our team wanting help as a customer — whether that's a business, an enterprise, a family, or an individual — you'll be directed to the ADT brand. If you're a player in the security industry, you'll engage with us in one of two ways. Either we simply serve as a provider of monitoring services — and we now hold the leading monitoring platform in Australasia. We went A1R1 officially last week, which, as far as we're concerned, makes us the number one player, given that there are two rooms, both A1R1, operating for the same business — or you'll work with us as a close partner, where we'll extend some of our relative scale to you to help improve your profitability and to help all of us grow our recurring revenue. A very straightforward go-to-market strategy. ADT is obviously also in New Zealand, so Australia and New Zealand. Tied together by some really clear values. We are here to be the leading player in security services.

Dennison Hambling

executive
#8

We're going to get there through a set of values that aren't trivial or immaterial to me or the team. Transparency is what our business is about. It's about being able to collaborate in a team environment, and it's about striving for excellence. We make no bones about that, and that's the bond tying all of us together across the business, and hopefully you're seeing the results of it today, which we'll get into. The 4C results Prezo. I think the big feature of this result — and there are probably three — is the fact that it's very clean. We recognize that this journey we've been on, as we've been putting together the business and the platform and the investments and the migrations from JCI, have lent to what I've often been told are messy accounts, understood. It's taken us until this time for those to be fully clean. That started a year ago. We knocked all the capitalization out. This year is a completely clear P&L year for that. It's now ceased with all the one-off costs, whether related to the refinance, the JCI transition, or the M&A costs. You're seeing the result of that in this quarter with an operating cash flow of $17 million, which I think most would agree is an incredibly strong result.

Dennison Hambling

executive
#9

So on underlying cash flow — if you’re willing to look past those $32.4 million of expenses from the prior quarter against underlying EBITDA of $38.6 million — I think that’s the item people will focus on, and whether “disappointment” is the right word or “interest” is. The reality is that we are pursuing a lot of increasingly larger-scale work and have attracted it to us. Two pieces of work in particular were affected at the customer level by senior-level staff changes, which deferred them, and that was disappointing. We had built a buffer in, but that sort of pushed it out, which just meant it hasn’t fallen in this period. In our opinion, all this means is that from a growth point of view the 2026 year is now looking stronger again, but will actually pull us up to where we expect it to be. Whilst we’re sorry for it, it was outside our control, and we don’t think it reflects anything other than just building a pipeline of new customers and strong value. What I am really happy to point to, though, is that the underlying earnings growth — when you take out the acquisitions and look at the business we had on a like-for-like basis, 2024 to 2025 — it’s grown 8.2%.

Dennison Hambling

executive
#10

I'd like to say that, in my view, that's a cautious way of looking at organic earnings growth. The fact is, the companies we bought — and I'm specifically mentioning Kobe and DVL, which came in this year — have gained from being under our ownership, since they've managed to secure work they might otherwise have missed out on. You could make the case that this counts as organic too, but we've kept that out of this discussion, which leaves us in very robust shape. We ended the period with $24 million in cash, and it's growing. We have the acquisition facility from NAB available, and NAB gave us terrific support over the last year — we're really grateful to have them with us as a key partner in our story and going forward, and that has allowed the board to begin the process of looking at capital management and what comes next. To make that easier, we're announcing today that we're setting up a buyback mechanism. We've named Morgan Stanley as the manager for it. This means we'll have complete flexibility as the cash accumulates to put that cash to sensible and reasonable use. One thing I've always said — and I should mention this marks three years for me as MD — is that this business is in effect run at board decision-making level by people with an investor mindset.

Dennison Hambling

executive
#11

When it comes to capital use, return on capital, and value of capital, those things are highly regarded and well understood in this business. What we're doing is just kicking off the process, so that as we get increasingly into rude health, we have the flexibility to put together some processes and plans and strategies around it. That's really what that's about. Looking a bit more carefully into the results here, I think the point of this chart, as you said, is operating cash flow in June of 2017. It goes almost right the way down. Reported and underlying are basically the same, less than $100,000 of M&A related sort of legal costs that fell in the period versus the $20 million of essentially non-recurring costs of the three quarters difference. If you accept those non-recurring, as I say, you get to a $32.4 million actual underlying operating cash for the year. I guess the read is that as you look forward, this business is going to generate, as it has done this quarter, very strong cash flows. In terms of the actual quarter itself and calling out the lines of costs, probably only a couple of things to notice here. We did have a little bit of inventory draws, about $0.5 million of inventory, I guess, down in this period.

Dennison Hambling

executive
#12

During the previous three quarters, we emphasized that we were putting money into the business and accumulating inventory. We've brought in new systems—sorry, for selling letters—new product as part of a service. This quarter benefited from a bit of movement in the opposite direction. We're increasing marketing. Our focus really is on growth. We devoted considerable time this quarter to our operational structure and our go-to-markets, which is why I presented the brands the way I did at the beginning of the prezo. Marketing went up, staff, admin—all essentially consistent with the size of the business. Obviously, the net interest line, where the advantage of the refinance is now genuinely flowing through the business. Ultimately, what I'd highlight is the cash in the bank. That rose $11.1 million during the quarter. The difference, naturally, is CapEx. The brief remark on CapEx is roughly $4 million. 75% of that is tied to the 3G CapEx in New Zealand. Just to flag it and remind everyone, that's a separate matter from what we handled a year ago when we discussed capitalization, CapEx, and 3G. In Australia, we were capitalizing under accounting policies inherited from JCI and go-to-market.

Dennison Hambling

executive
#13

For New Zealand, and now including our accounts, we aren’t capitalizing that spending. That’s CapEx for systems we own and are effectively leasing back—mostly medical systems. It’ll abate. This is roughly the peak, then it rolls off into next year. I’ve mentioned a figure there that will be refined further when we get into the financial year, around the full-year result. It’s an AGM that for this business that CapEx will come in below $10 million. Between operating cash flow and cash in bank, really that CapEx piece is four. For Intelligent Monitoring Group, underlying business CapEx is really the same as underlying depreciation, which is a $2 million-$3 million number. You simply have to add that medical business in New Zealand on top, which on a normalized basis outside the 3G rollover—the fleet’s stay-in-business capital—is about $4 million a year. Ultimately, once we come out of the 3G period, we see CapEx for the wider business falling to that kind of $7, $8, $7 million number. Any investment we need to make will only be around building systems or IT or comparative advantage, outside of M&A, obviously.

Dennison Hambling

executive
#14

That's a solid narrative. On EBITDA, we already put those figures out ahead of time. I've spoken to it, and we've laid out the breakdown. Really, this is simply the bridge that illustrates growth in the underlying business. As I mentioned, the fact is the acquisitions did comparatively better while underlying growth came in comparatively weaker against what our guidance had anticipated. That relative shortfall — and it's an awkward term to use, since the underlying business is performing very well and we're feeling quite confident — came down purely to timing. Our confidence is high. I'd likely just stop for a moment and note this, because it's been something of a quarter-by-quarter pattern. Exiting this year, we're positioned on a very solid footing as we look toward 2026, with another significant rise in EBITDA and consequently cash flow as we move into 2026, based on where the business stands right now. To close out the 4C remarks, this represents the culmination of reflecting back across the past three years and at last being in a position to genuinely confirm what we've been telling you. To everyone who has stood behind us throughout that period, our gratitude is enormous, and we hope you feel that confirmation yourselves, having put your support behind what is truly a strong business.

Dennison Hambling

executive
#15

Like I've said before, over the past six months and more, our real focus has been on figuring out how to speed this up and create a service business that's genuinely excellent and built to last. The buyback I mentioned is essentially about options. Being in this kind of position is a great thing, and we want to be sure we're weighing every option available and that we truly keep driving strong growth for shareholders. I made a remark regarding the earnings. The truth is that earnings rose in the second half of the year, just as they had in the first half. We're simply pointing out that if you look only at the second-half base — a conservative read on what is probably the actual run rate — you'd anticipate seeing quite solid growth as we head into 2026. It's our intention to provide — we're in the middle of internal budgeting right now, and we really want to make sure the work gets done properly and that we plan this business well, not only for this year but for the next three years at this point. What we plan to do is go through an internal round, which we'll shape during September, with the aim of giving full guidance for FY 2026 at the AGM in October.

Dennison Hambling

executive
#16

We're going to devote a lot of time at our results plan in August — we're aiming for the 26th of August — to walking through our pipeline and demonstrating why our confidence is high, covering what we're examining right now, what's in hand with us, and what lies ahead for the business. My final point is that with the balance sheet in this condition as well, we believe we have a strongly credentialed route to deploy M&A strategically around building value — not merely in the price paid, but in how we've integrated and how we've pulled this business together. I feel genuinely excellent about that. That has always been my benchmark: being extremely careful, highly selective, yet ready to act when it makes sense for us on a medium-term basis. We're positioned well to carry on that journey. To pursue anything we might be considering at present, equity would not be required. You should expect us to keep selectively building this business with our capital or shareholders' capital as time goes on. When you consider us, what has really paid off, I think, is the A1R1 certification — and I think the current conversations surrounding the childcare sector, privacy, and access to video and surveillance have underscored both the edge we've created by investing in the platform we have today and the chance for us to broaden that edge as time goes on.

Dennison Hambling

executive
#17

The clearest way I can put it—what I believe has unfolded on this journey, and my hope is that you can see what we're doing and fill in the picture—is that when we invested, as we did 3 years ago, in a really difficult moment, when we were over-geared and under-capitalized, and we asked shareholders to help support us in investing in our platform, that is what gave us the leading platform. We've since been able to put money into building scale and reach, and that is drawing in large customers. In my view, it has placed us at the industry's forefront, and that is making our business better, which produces the result you're seeing today, and that is now giving us the opportunity to keep investing and to build comparative scale and advantage, which I believe is going to create, and keep creating, a fabulous company. I definitely sense that is the internal environment in the business, and the understanding we have. Hopefully that makes sense to people, and I'm happy to talk about it. Let me just close. Again, what is IMG about? Really, this is a strong demonstration of what we can do on a purely physical level. I'll just share the story here.

Dennison Hambling

executive
#18

This is a Storage King. I won’t say where it is, for customer privacy. We also won’t be making this video public. It’s for this forum only. Basically, what you’re seeing here is a few individuals—you can see them on the screen—attempting to enter the building. By this point, our live monitoring team has already spotted them. In this instance, the team was operating out of Port Lincoln. They carried out a threat assessment. At that moment, the operator has a few choices available. I want to give a shout-out to Ben—Batman Ben, as we call him. The operators who do well end up being Batman or Bat people. The assessment was: do I frighten them off, which our technology lets us do now, or at least attempt to scare them off and distract them, or do I believe we can actually catch them with the police before they finish or carry out what they’re doing? Here, the call was to let them keep going and see whether we could get the police there. The police had already been notified. I’ll show you the short video. You probably won’t be able to hear it, though.

Dennison Hambling

executive
#19

There was some loud shouting going on, which is allowed. You probably couldn't have heard it, but that was the police chasing after the guys who were yelling at them. They got them off camera. I'm told it was a suburb state of origin kind of tackle, and they apprehended both of them. On our side, ever since we began using this technology, from the beginning of the year, we've made apprehensions. We've had 21 events where we've apprehended over 30 people together with the police. The average police response time, from somebody attempting to get in to them arriving, has been about nine minutes. That's the difference. Anyone who asks why I would have monitored security — you're right. If you're looking in the rearview mirror, perhaps. I'd still argue there are cases and ways it can be used to your advantage. This is what we do today. This is the opportunity we have. We think the market — we think we currently are the leaders for sure. We think this is a multi-billion dollar opportunity to apply across Australia as one of several segments of what we can now do with technology, which sort of validates the investment we made. I'll draw a line there. I hope I haven't overtalked.

Dennison Hambling

executive
#20

My apologies. I'll wrap up with the slide showing the market stats, and I'll discuss those at a later point. I'll keep it displayed in the background. Go ahead with whatever questions you have, Mark.

Mark Tobin

executive
#21

Thanks. Appreciate it, Dennison. Yeah, we have a whole bunch of questions here. We won't be able to reach all of them. I'd like to say sorry to those folks right now if your question doesn't get answered. I'll pass them along to Dennison and Shane. Hopefully.

Dennison Hambling

executive
#22

I'll mention that. Look, you have our information and our phone numbers. Please don't hesitate to contact Shane, Jason Biddell, our CFO, or me. All of us are ready to walk you through the figures however you'd like.

Mark Tobin

executive
#23

All right, great. To start, I'd like to address those 2 large service contracts that were deferred. Once those new executive appointments begin over there at some point — say in FY 2026 — how confident are you that you know it will come back online?

Dennison Hambling

executive
#24

Well, no, look, I suppose nothing in life is guaranteed. We are deeply focused on the one we've genuinely been targeting hard. One was somewhat opportunistic, though fairly significant. There's been a staffing change that might take some time. I think it simply requires them coming back to the table, which we've witnessed before on our journey. For sure, we saw that with Regic Shop this year, when the takeover halted them. We were just about set to go and pick them up. The takeover happened. They scrapped it and stopped doing everything. We figured that was gone and done with. Within a month, they returned. The new owners said that while they're changing this business entirely and overturning it, they do need a proper security supplier across the country to handle this for them and bring us up to spec on a global basis. We want you to push forward even though we're not doing anything else. It returned to the table. I think one of them is likely in that camp. The other one we're very active on. I'd certainly look forward to updating people in August about where that stands. It's absolutely a meaningful contract, but it'll also be a real leading contract for the industry.

Dennison Hambling

executive
#25

For people in the industry who get it and are familiar with that contract, it'll really solidify our position as a leader — the leader in enterprise security, in my view.

Mark Tobin

executive
#26

You asked about the momentum in video guarding services that we saw in FY 2026. Dennison, maybe you could just touch on the pipeline and any investment that's needed to meet demand for that rollout.

Dennison Hambling

executive
#27

So look, right now there are two parts to the investment. The first is marketing. You're going to notice the ADT brand showing up far more often than it has before. In newspapers, with banner ads, you'll come across some editorial-style content in various places. You'll likely see me appearing a bit as well. I think the whole point there is to begin spreading the message so people can actually see it. Once people see what we're capable of, they buy it virtually every time. Our uptake rate has been extremely high, but we haven't taken it wide. That process is now getting underway. On the other side, we're very aware that even with our unique reach and scale on the technical base, we'll never on our own be able to serve what we believe demand will be. What I want to steer clear of is returning to the market and saying, wow, I've built a $50 million, $100 million pipeline in guarding over the last two months, and then returning six months later and saying, well, you delivered $5 million of revenue. What happened? And hearing, well, we simply can't get through the work quickly enough.

Dennison Hambling

executive
#28

This is exactly where our signature partner strategy really matters. If you're in Sydney, Azure Conference takes place at the back end of Sydney. It's the industry conference. We'll be launching our signature partnership brand together with 20 trusted partners. The whole point is giving us low capital reach to drive guarding. To answer the question, there's an investment in signature, and there's also an investment in marketing. No CapEx is required, though. It's entirely about operational investment to grow capacity and capability.

Mark Tobin

executive
#29

Alright, one more item here, just to clear up a few of the cash flow pieces. One of them is a $500,000 benefit to operating cash flow that came from an inventory drawdown.

Dennison Hambling

executive
#30

Good question. I can answer that since I see where you're headed with it. There were four components — three components, sorry — that were probably just slightly positively abnormal. While it's a clean result, there is business movement in the quarter. $1.3 million of income in advance from a government, essentially a government contractor, or the New Zealand government, frankly speaking, paying up to June. It's a process they follow. There was $0.5 million of inventory, which I've already called out, benefit. There's also the AASB card leasing benefit, where you shifted that cost out of operating cash into the financing cash line, which you'll see. That delivered a $0.5 million benefit in this result. That $17 million operating cash flow is probably $2.3 million positive from what you might term one-off factors that will normalize. Beyond that, though, it's clean. It's clean in terms of business as usual. No one-off costs apart from what we've called out. It's what we would expect to reflect the business as it stands on a steady state basis.

Mark Tobin

executive
#31

And on the second part of your question, NZ4G — though I think you mean 3G — are you essentially saying that the investment related to that will have wrapped up or ceased around the end of the second half of 2026, basically by the close of FY 2026?

Dennison Hambling

executive
#32

Correct. Profiles are declining. The tricky part is that this will persist for as long as the carriers choose to keep their 3G networks running — which is exactly the situation we observed in Australia. That's outside our control. Based on our assessment, you ought to see that figure fall each period until it disappears. My view is that the end of 2026 is the most probable point. I could picture a small residual, though I'm referring to roughly $0.5 million perhaps into the, sorry, into the latter half of 2026. It's certainly gone in 2026. The first half sees it coming down, likely gone by the second half, and there might be a tail — that's how I'd frame it.

Mark Tobin

executive
#33

All right. There are three or four questions about capital allocation. I'll combine them into a single one, and that includes one from a shareholder in Canada who's clearly enthusiastic — according to what I have here, likely one of the first attendees we've had from that country. So, on deciding how capital gets allocated, my assumption is that it will be on the board's agenda come August. You're actually receiving the final results in August, along with budgeting, but there are plenty of questions about buybacks of shares, dividends as opposed to acquisitions as opposed to putting money into the business that already exists. Perhaps we could elaborate on that a little if possible. We might finish up at that point. That accounts for roughly four questions.

Dennison Hambling

executive
#34

That's fine. I’d likely point everybody back to the equity raise slide we did in, I believe, around September of last year. On that slide, we actually showed our record on acquisitions — the prices paid and the value essentially created. It appears we can still acquire high-quality businesses. These are high-quality operations, but with long-standing customer bases that last, and high-quality staff who keep growing. In fact, they probably grow faster under our ownership than they did before, for, you know, three and a half times EBITDA. I’ve been very clear: I don’t want to see creep. We’re very disciplined about that when we discuss M&A. For us, M&A typically isn’t a conversation about value. While that’s true and it makes sense for us — and I’m a shareholder myself — I still would prefer that we grow and build scale. We’re seeing the benefit of it. We’re seeing customers come to us because of it, and it’s giving us access to, increasingly, more and more equally good people and to build this leadership. I think capital allocation at this stage still has to be weighed against our ability to deploy capital well. That’s not — while we have lots of opportunity, we’ve also got a high bar, and it’s not just value.

Dennison Hambling

executive
#35

It comes down to sustainability and whether we can actually execute. Like I've said, I'm very, very clear on this. If I'm never remembered, that doesn't bother me much, but being remembered for blowing up a business because we over-acquired is something I don't want. All of it gets weighed up against each other. I think the bigger point is that what we've felt during this period is we might start generating far more cash than we can deploy, actually. That period might arrive sooner than we thought. I think also I'm old enough to remember the 1987 crash. There are periods where you can wake up and all of a sudden, notwithstanding you run loving what you do and all that sort of stuff. I personally remember buying a company in the GFC for a 7.5% dividend yield and it grew year on year, but the major shareholder had to exit because they just needed liquidity. I'd like the board and ourselves to be in the position to not have to wait a week, get advisors, try and put a buyback in place to be able to benefit. Should something like that happen, I'm not predicting it. I'm just saying, you know, life's unpredictable. I see it as costless insurance that we can use as shareholders, and I include myself in that, all of the people on this call who are shareholders, money, you know, to maximize the opportunities that sit in front of us, and our intention is to do that firmly.

Mark Tobin

executive
#36

Once more, my apologies. We weren’t able to get through every question, but I’ll forward a copy to Dennison Hambling, and he can address them. The full-year result will be released in a couple of weeks, so perhaps in the updated presentation I can work some of those answers in. As he mentioned, please contact the team directly. Dennison, many thanks for being with us this morning.

Dennison Hambling

executive
#37

Thanks very much. I really appreciate that. And thank you all for the backing and the confidence you've shown. Looking back, it was 3 years ago that I stepped into the CEO role. At that point our market cap stood at $11 million, and our gearing was above six times EBITDA. This quarter, it's genuinely gratifying that the cash we've put in the bank matches what our market cap was back when this team got going. That result comes out of choices we made earlier on. What holds our attention now is really the inputs feeding into whatever lies ahead of us. That's where our enthusiasm sits — we truly believe we're positioned well, and hopefully we can build a durable, genuinely high-quality leader across Australasia in the service we provide and the space we operate in. I'm grateful for the interest and the support, and I'd be glad to catch up with people over the next little while.

Mark Tobin

executive
#38

Thanks, Dennison. Our next presenter is waiting patiently in the wings, Mr. Steven Lydeamore. Steven, good morning.

Steven Lydeamore

executive
#39

Morning to you — how’s it going?

Mark Tobin

executive
#40

All right, Steven — go ahead and start sharing your presentation deck, and I’ll tell you when I’m able to see it.

Steven Lydeamore

executive
#41

Let me take care of that.

Mark Tobin

executive
#42

If that happens, I can picture it. If you'd like, just switch to full screen on the hers, into slideshow mode. There we go. That looks perfect, Steven. You can take it away whenever you're ready.

Steven Lydeamore

executive
#43

Alright, thanks a lot, everyone. It has been a bit of time since my last update on Coffee Microcaps — I believe that was in March. Things have been extremely hectic for us, and we just announced our annual sales, which felt great, because we were finally able to hit that forecast we had publicly set of $7 million in revenue. We came in above it at $7.3 million. If you remember the earlier stories, before COVID the product on its own generated at most $2.5 million in revenue. During the COVID stretch it fell to nearly $0. In the three years since I came on board, rather than keeping Travelan as a side project of a drug development company, we have directed resources and effort into marketing a rather distinctive product for preventing travelers' diarrhea. The results are beginning to speak for themselves. This is only the start. Let's move into it quickly. Our FY 2025 results are not yet through the audit process — just a safe harbor note on that. A brief look at the company's financial snapshot: Travelan is not our sole product. We also offer Protectin in Australia. We are a drug development company, and we have several clinical programs.

Steven Lydeamore

executive
#44

Turning to Travelan itself, there’s a large trial involving 866 subjects, and it’s being conducted and financed by the U.S. military. That study is now finished. Every one of the U.S. and UK military personnel has been randomized, deployed, and has taken the drug. Right now they’re in the middle of analyzing the data. We expect topline results from that trial in October of this year. That’s pretty exciting for us. As you’ll remember, we have Travelan Phase Two. That was a controlled human infection model study that was completed. We haven’t yet asked for the end of Phase Two meeting with the FDA. We’re awaiting the results from the Uniformed Services University study, which is quite informative for the clinical trial protocol before we request that meeting with the FDA. We do expect to do that after those results come in. For IMM529, which targets Clostridioides difficile infection — CDI or CDIF for short — we have a protocol ready to go. We’re completing the final steps of preparing the IND. That’s the investigational new drug filing, which we hope to submit to the FDA by the end of September. As you can see, there are plenty of near-term milestones on the clinical pipeline. There’ll be an update on the first quarter of the new financial year, FY 2026, in around mid-October for those September sales results.

Steven Lydeamore

executive
#45

Just to go over that again, as you can see down below, we wrapped up the financial year at the end of June with $7.3 million in revenue, which is up 49% on the prior year. That growth isn't all coming from Australia. Importantly for us, North America — so that's U.S. and Canada — we had sales of $2 million, up 76% on the prior year. Given the larger population of people, we're seeing that as a great growth driver for the company moving forward. We continue to evaluate new international markets and also to add additional products to our portfolio. You may have read that we have secured one such asset with a license from a company in Sweden, a product called Pro-IBS for irritable bowel syndrome. We're working very hard on getting ready for launch of that. The order for opening stock has been placed. We anticipate receiving that in the near term. We're planning on launching the first quarter of next calendar year. If possible, we will try to launch it for the Christmas period here in Australia. I thought this might be useful. Last time I presented at Coffee Microcaps was back in March 2025. This is a comparison of what was the status back then to now.

Steven Lydeamore

executive
#46

At that time, I was reporting record sales of $4 million for the half year. I've just told you that we've kept that growth going and hit record sales for the financial year just ending, $7.3 million, up 49%. We had submitted the Phase Two clinical study report to the FDA. I'll just let you know that we're waiting on the Uniformed Services University trial results before we request the end of Phase Two meeting. I had reported that we'd finished recruitment. Just now, we're reporting that all of those people have been randomized, deployed, and the quality review of the study data is initiated. Top line results are anticipated in October. Back then, we had IMM529. We had that successful pre-IND meeting with the FDA. Updated dates for the milestones for this program are submission by the end of September. We're hopeful that we could get FDA approval of that IND, which would allow us to start Phase Two studies by the end of this calendar year. We reported we started a new program in collaboration with Monash University, IMM986, for vancomycin-resistant enterococci. This is quite a big problem for antimicrobial resistance in Australia. Hospitals in Australia are finding it difficult to treat patients to get this.

Steven Lydeamore

executive
#47

We've produced colostrum with vaccines that were designed specifically to target VRE. Right now, we're doing in vitro method development prior to starting preclinical studies. Regarding that new distribution agreement for Pro-IBS, just to restate the dates, the stock is anticipated to be delivered in Q3 of this calendar year, with a launch in Q1 of 2026. We're hopeful a launch could happen late this calendar year. For anyone new to the Immuron story, let me give you a bit of background on Travelan. This is a billion-dollar market. To be clear, that billion-dollar market currently consists primarily of products used to treat travelers' diarrhea after someone comes down with it. Think of products such as Imodium or Gastrostop in Australia. That's Loperamide, the generic drug name, plus rehydration salts and similar things. That is a very large market. What we're aiming to do is shift the market from treatment to prevention, because we offer the ability to stop you from getting it in the first place, and given that the frequency of travelers' diarrhea ranges anywhere from 30% to 70% according to the Centers for Disease Control in the U.S., it's clear that if you're traveling — an Australian going to Bali, or say Americans going to Mexico — the chances of getting travelers' diarrhea are very high.

Steven Lydeamore

executive
#48

That would wreck your vacation. Paying a little to take Travelan ahead of time and while you're traveling is a minor cost by comparison. The product rests on a proprietary vaccine. We have 2 vaccines—a multi-strain one and a single-strain one—that we use to inoculate cows. Those cows generate polyclonal antibodies, and those antibodies are aimed specifically at ETEC—that is, Enterotoxigenic E. coli—which contributes more than anything else to travelers' diarrhea. It can also act on other bacteria that are similar in nature to E. coli. We've run many studies with various branches of the U.S. military demonstrating this effect. It's strongly capable of preventing travelers' diarrhea. Our clinical studies have demonstrated a preventative effect of up to 90%. So how does it work? We can bind and neutralize to prevent. I won't walk through every detail here, but the slide deck will be posted on our website. You can read more there about how it works. It's a rather unique technology that nobody else is currently using to make a product like Travelan. I like this graph. I've already discussed the numbers, but seen graphically, you can tell that FY 2024, the financial year before this one, was an excellent year for growth.

Steven Lydeamore

executive
#49

We posted record sales growth for that year. And in the year we're in now, we haven't just grown sales — you can look at how that line is trending. It's climbing at a faster rate. We're beginning to see real traction. Growth keeps coming in Australia, our core market and the biggest source of revenue. The big-population markets up in North America are now beginning to add meaningfully too. As much as $2 million in revenue for the financial year that just wrapped up, and at a higher growth rate. That comes on the strength of solid sales gains on amazon.com in the U.S. Over in Canada, we've locked in distribution across 10 pharmacy and grocery retailers. There's a lot more still to do in the Quebec regions as well as the Atlantic provinces. We're at work on that through this financial year. Just to give you a picture, a snapshot of where things stand. In Australia, we're in basically every pharmacy banner group. Through FY 2024, we succeeded in landing primary listings with several pharmacy chains. In Canada, the setup works much the way it does in Australia. There are big banner groups. Shoppers Drug Mart is the counterpart, so to speak, of Chemist Warehouse in Australia, the biggest banner group. We hold listings there.

Steven Lydeamore

executive
#50

You're able to look at several of those other groups too. In contrast with Australia, we also participate in grocery. Within Canada, Loblaws and Sobeys operate as grocery chains. And in Canada, which differs from Australia, those grocery chains include pharmacies as well. That's a solid chance to take the expertise and the success we've achieved in Australia and bring it over to the Canadian market. The U.S. market differs somewhat, since unlike Australia and Canada, it permits health claims on labels. When it comes to discussing prevention of travelers' diarrhea, there are limits on what we're allowed to say in the U.S. We lean more heavily on social media marketing and on targeting products in a different manner. At present, we're largely doing that through amazon.com and walmart.com. We still keep selling product via Passport Health, the biggest chain of travel clinics in America. We're fairly happy with the growth rates across both of those North American countries, and equally happy about our capacity to keep growing at double digits in Australia. What's our approach? It involves a range of activities that we're carrying out. As you'd expect, in Australia and Canada we run the usual retail-focused promotion. We additionally put a lot of effort into in-store positioning and promotion.

Steven Lydeamore

executive
#51

We collaborate with pharmacists and pharmacy assistants to ensure they grasp Travelan — how it functions, what it's good for, and how to pitch it to customers, since they act, in a sense, as our sales force inside the store. Selling it isn't hard, because nothing else on the market matches Travelan's capacity to ward off travelers' diarrhea with that 90% preventive effect I mentioned earlier. In the U.S. we do this, and for Australia and Canada too. We put substantial effort into social media marketing and targeted advertising. Should you be Googling exotic travel destinations or travelers' diarrhea or anything along those lines, a Travelan ad will undoubtedly appear on your screen discussing the benefits of using it. Let's return to the pipeline. As I said earlier, we hold multiple assets across multiple clinical programs. The travelers' diarrhea market. Our aim is to secure approval for Travelan, currently sold over the counter, as a medicine in the U.S. market. As estimated by Lumanity, a top market evaluation firm in the U.S., the potential market size for that is roughly $100 million in the U.S. market alone. That same firm, Lumanity, has estimated a U.S.

Steven Lydeamore

executive
#52

For Clostridioides difficile infection, we see a market of $400 million for IMM529. We raised that figure during the last financial year, since our focus shifted from second-line therapy to primary therapy. Our successful pre-IND meeting with the FDA centered on a clinical trial protocol that will be standard of care. It compares the antibiotic used to treat C. difficile against standard of care plus IMM529. That is first-line primary therapy, and it represents a much bigger opportunity. This ranks among our near-term milestones. As I said earlier, we are getting ready for that IND submission, and our best estimate right now is by the end of September, with a target of having it approved by the end of this calendar year, which would let us move into phase two clinical studies next calendar year. IMM986, for vancomycin-resistant enterococci, is in preclinical activities. We expect the preclinical results in the first half of next calendar year. That covers in vitro, meaning test tube, and in vivo, meaning animal data, which we hope will show that our vaccines and the colostrum we have used from it have produced a therapeutic asset we can advance into clinical studies.

Steven Lydeamore

executive
#53

Here are a few more specifics underpinning the figures I cited earlier — $100 million for IMM124E, which is the active drug substance in Travelan, and $400 million for IMM529 targeting C. difficile infection. I won't dwell on these, but they offer some insight into how those forecasts were built. At the bottom there, you can see our current position. IMM124E has finished phase two and is getting ready for phase three, and IMM529 for CDI — we're expecting IND approval, which would let us begin phase two in 2026. A bit about IMM529 and why it excites us so much. It's a non-antibiotic, so it avoids the antimicrobial resistance issue. First-line therapy is what we're aiming for. Why do we believe we can succeed? We've run animal studies, and the efficacy — the results from those studies — appear below. We've demonstrated that we can not only prevent but also protect against recurrence. That means stopping it from coming back. To be clear about what that involves: when you treat with the current primary care, which right now is antibiotics, quite often patients experience recurrence — meaning it returns. That happens more than once. With our product, a non-antibiotic, that problem doesn't arise, and it also has the ability to treat those recurrent patients.

Steven Lydeamore

executive
#54

We can also address primary disease. If someone didn't receive our product for prevention and ends up contracting C. difficile infection, our product could be used as a treatment. These are animal studies, and human clinical studies are needed to demonstrate that this carries over to humans. At this point in animals, certainly, you're able to see statistically significant results demonstrating prevention, protection, and treatment of primary disease for C. difficile infection. This is accomplished via a product that we believe is the first with multiple mechanisms of action. It goes after not just toxin B — the toxin C. difficile employs to infect a host — but also spores and vegetative cells, which are part of how it operates. We hit all three, which is likely the reason we obtained such strong efficacy results in the initial clinical trials in animals that you saw here. This is a summary, if you will, of that phase two study for IMM124E, Travelan in the controlled human infection model study. It was interesting that efficacy came in high, though not as high as earlier Travelan studies that were conducted three times daily. This study was once daily.

Steven Lydeamore

executive
#55

Even so, we did achieve some success, demonstrating statistically significant results when it came to halting diarrhea of any severity, as well as less significant events. Those results were very pleasing to the military. They, together with us, are also looking forward to getting the results of that Uniform Services University study, which used twice daily dosing. That should give us a solid idea of what dose to take into phase three. As you recall, the original study is three times daily, with up to 90% protective effect, while once daily is around 40%. Results from the new U.S. study with twice daily dosing will be coming out in October, which is not too far away now. The plan for IMM124E, once we have that dose selection and that end of phase two meeting with the FDA, is to move into phase three trials. Every one of those trials will take approximately two years. That will lead to a BLA submission and another 12 plus months for approval. Details of what that trial looks like are set out below here. We are hopeful that when we obtain these Uniform Services University study results, which come from a real-world setting, so a phase three-like trial, it may be enough to get into the CDC Yellow Book guideline, which is what doctors consult when considering what to prescribe to their patients before they head off on vacation to a high-risk region.

Steven Lydeamore

executive
#56

Even prior to securing FDA approval, getting included in those guidelines—whether the CDC Yellow Book or possibly the International Society of Travel Medicine guidelines—would unlock a substantial portion of the U.S. market where we currently have no presence. Since we lack label claims for travelers' diarrhea prevention in the U.S., unlike in Australia and Canada, we are restricted to patients who avoid visiting a healthcare practitioner, self-diagnose, and pursue treatment on their own. That likely represents under 25% of the market potential. This is exactly why the findings from the Uniform Services University study, scheduled for release in October, have us quite enthusiastic. There are three upcoming milestones to pursue moving forward. First, continued revenue growth along with the growth drivers I already mentioned, plus a new product launch—ideally before this calendar year concludes, but definitely within the first quarter of the next calendar year. Second, clinical milestones are approaching in the near term. We have that September IND filing for IMM529. We also have top line results from the Uniformed Services University study—that large 866 patient study—in October. Additionally, we may see some other milestones tied to IMM986, the VRE, vancomycin-resistant enterococci program, over roughly the next six months.

Steven Lydeamore

executive
#57

I'll stop there and take any specific questions you may have. For anyone who's technically inclined, in the back of our deck on the screen I've put clickable links to every one of the supporting publications. Of course, it doesn't cover unpublished material, but it does include the publications where peer-reviewed articles have appeared demonstrating how Travelan and IMM529 work.

Mark Tobin

executive
#58

Thanks, Steve. We have a few questions lined up now, so I'll get right into them. Travelan's revenue in the second half doesn't look as strong as it did in the first half. What drove that? Should we be considering seasonality between those two halves?

Steven Lydeamore

executive
#59

Seasonality does exist, and it differs from one country to another. Peak travel periods are a real thing. Take the U.S.: spring break is a major travel window there. It's comparable to Australia's winter, when folks head to warmer places such as Mexico or the Caribbean — though winter obviously falls at a different point in the calendar than it does in Australia. The main driver behind the sales gap isn't seasonality at all. It comes down to what I mentioned earlier. Over the last financial year in Canada, we secured those listings with retailers, pharmacy and grocery alike. In Australia, we likewise landed primary listings with several big pharmacy banner groups, Terry White Chemists being one example. Once new listings come through, wholesalers stock up. A wholesaler stocking period kicks in, and that hands you a chunk of sales. Those are the sales we book. Our recorded sales are sales to the wholesalers. Naturally, consumers purchase from wholesalers before they actually use anything. A timing gap exists there. That's the chief explanation for why sales differ between one period and the next. Our attention isn't so much on what we sell out to the wholesaler — it's on what wholesalers sell out to consumers.

Steven Lydeamore

executive
#60

That's the source we rely on—IQVIA data. What we've observed is robust growth from one period to the next, with steady expansion across markets, which shows Travelan keeps selling extremely well. It isn't on this slide deck, but I've shown before that in Australia, within that digestive health diarrheal category, we've held either the number one or number two SKU position. Our aim going forward is to remain in that spot.

Mark Tobin

executive
#61

There's a question about IMM986 and the preclinical data. According to what was said before, those results were expected in August 2025. Folks are just following up on that. Does that timeline still hold?

Steven Lydeamore

executive
#62

No, it isn’t on track. Preclinical studies, sure—but research and development is called that for a reason. Development carries risks. Maybe I should walk through what goes into creating a new asset like this. Our technology works by developing proprietary vaccines aimed at a particular pathogen. With Travelan, that pathogen is ETEC—Enterotoxigenic E. coli. For VRE, it’s vancomycin-resistant enterococci. Those vaccines have been fully developed. We’ve vaccinated cows. Obviously, there’s a stretch of time when a cow has to go through pregnancy before it can produce colostrum. That’s been done. We’ve produced that colostrum. Assays have to be developed before you can run preclinical experiments. We’ve faced some difficulties getting the assays as robust as we’d like. That has created a bit of a delay in the program. There are two kinds of assays. We have ELISA assays and also Western Blot. We’re focusing on ELISA first, and then we’ll do Western Blot. We’d like to complete both successfully before moving into animal studies. Rather than August for the initial in vitro preclinical data, it’s likely to be—I haven’t given a target timeline yet, because we really don’t know, since we don’t have those assays yet.

Steven Lydeamore

executive
#63

The moment I have any update on what that date will be, we'll get that out to the market. It'll be sometime in 2026.

Mark Tobin

executive
#64

All right, good. Perhaps the full-year result will be available. Perhaps by August, that particular study will be somewhat clearer. A question comes up regarding funding — specifically whether there’s further rollout of these studies, moving from one phase to the next phase, and expansion of Travelan. On the cash side, I know a lot of this work is already funded by Uniform Services or other partners who are kind of helping to fund a lot of this research. Maybe just touch on — and I know the foresee will probably be out in detail sometime next week — maybe just touch on the need for funding moving forward, if any.

Steven Lydeamore

executive
#65

All right, I'll briefly address the guidance question. We're lucky in that guidance isn't something we're required to provide, but our preliminary annual results are scheduled for release at the end of August, and those will give you an update on CAS along with the complete profit and loss and cash flow statements and similar items. On the cash front, the last figure we reported was at the end of December, when we held slightly more than $7 million. Naturally, we've been using some cash, so by the end of June the balance sits a bit below that level. As for raising capital, we have in fact done so, through an ATM facility we had set up in the U.S. market. When we announced our sales results, which set a record and showed significantly high double-digit sales growth, the U.S. market responded very favorably. There was substantial trading volume at prices higher than those on the Australian market. We used that opportunity to place roughly US$2 million of stock into NASDAQ, which has given us enough funding to begin those IMM529 clinical trials.

Mark Tobin

executive
#66

Perfect. A question about the top line results for the Travelan trial. I'm just wondering, why is it taking so long? Is it simply that, you know, we're in the middle of the U.S. holidays? Is that just kind of, you know, trying to get anything done in December or January in Australia? Or is it kind of the flip side of that — trying to get anything done in July or August in the U.S.?

Steven Lydeamore

executive
#67

No, that's not really what it's about. The top line results we're waiting on aren't something we're running personally ourselves. This trial was conducted and funded by U.S. military resources — that's the Uniform Services University. It's a large study, with 866 subjects, U.S. and U.K. military personnel. The protocol, which was available on clinicaltrials.gov, if you take a look at it, has not only the primary endpoint focused on diarrhea but multiple secondary and exploratory endpoints as well. It's a data-rich study. The quality review and data analysis for it take a long time, which is why there's a delay in reporting out that top line data. It's good, though, that this rich data is very, very useful, because it will inform us as to how things go forward for the phase three studies for Travelan. It's useful information before going into the end of phase two meeting with the FDA. I mentioned before that we've got two controlled human infection model studies showing different results for three times daily versus one time daily. This study is not a controlled human infection model study. It's in people who have traveled to high-risk regions, a field study, much higher relevance to a phase three study, and it's also twice daily.

Steven Lydeamore

executive
#68

We're going to get dose-ranging data, and we'll learn which patient types it was effective in and which bacteria it was effective against. Those working in this field know that ETEC isn't the only cause of Travelers' diarrhea. Other bacteria are involved, and viruses and parasites too—there are all kinds of reasons someone comes down with Travelers' diarrhea. This study is going to give us a great deal of information about where it works and where it doesn't, and it will strongly shape the protocol for moving Travelan into phase three.

Mark Tobin

executive
#69

Alright, Steve, we've run a bit past our time, and I don't want to eat into any more of your morning. Thanks so much for returning and being with us once again. We'll be keeping an eye out for the portfolio results toward the end of August. As you mentioned, plenty of studies are wrapping up, with data coming out from now through the end of December. Yeah, lots of milestones for folks to watch over the first half of 2026 here.

Steven Lydeamore

executive
#70

Yes, that's really solid. We're pretty enthusiastic about it — both the upside on revenue and the clinical milestones that demonstrate our platform technology carries meaningful value. Thanks once more for your time. Viewers, here's how to reach me: that's my personal email and phone number. Should you have any follow-up questions, don't hesitate to get in touch.

Mark Tobin

executive
#71

Thank you, Steve, and thank you all for being on this morning's call. That's where we'll end it. There's another webinar coming next week, and information about it ought to go out on Monday or Tuesday. It'll take place on Thursday morning next week instead of Friday morning. I hope you're able to be with us then. We're just working to finalize the last 1 or 2 presenters and a few other details. Have a great weekend, everyone, and we'll speak with you next week. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Intelligent Monitoring Group Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Intelligent Monitoring Group Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Intelligent Monitoring Group Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.